Asciminib Combination Therapy

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Sorting 6 by

Memorial Sloan Kettering Cancer Center
New York, NY
Fully Open
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Bergen
Montvale, NJ
Fully Open
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Monmouth
Middletown, NJ
Fully Open
  • Accepting patients
  • Show Principal Investigator
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, MI
  • Accepting patients
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.